Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
In osteoporosis hospital visits for patients aged less than 50 years old, bone mineralization promoters and combination medicine preparations are still the main ones, and the bone mineralization promoters are mainly vitamin D active metabolites, while the proportion of traditional single calcium preparations is low, and there is no significant increase.
Source: Summary of different types of medicine use. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This multicenter and cross-sectional study was in line with the guidelines of the World Medical Association and the Declaration of Helsinki.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
A retrospective analysis of anti-osteoporosis medication trends among patients under 50 years old in nine major regions of China from 2016 to 2019
Cross-sectional study · PeerJ · 2025
Original publication title
A retrospective analysis of anti-osteoporosis medication trends among patients under 50 years old in nine major regions of China from 2016 to 2019
© 2025 Chen et al.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This study aimed to assess the national trends in osteoporosis prescriptions among Chinese adult outpatients aged less than 50 years with osteoporosis, from 2016 to 2019.
Source: PurposeAbstract: What methods does the paper describe?
Prescriptions for adult outpatients with osteoporosis from hospitals in nine major areas were extracted from the database of the Hospitals Prescription Analysis Cooperative Project. Trends in the annual prescriptions and expenditure of osteoporosis were analyzed.
Source: Patients and methodsAbstract: Results
The number of osteoporosis hospital visits showed an increasing trend year by year from 18,412 in 2016 to 23,447 in 2019 (P = 0.029), and the corresponding cost increased from 2,083,872.94 Chinese yuan (CNY) to 2,643,508.59 CNY in 2019 (P = 0.032). The result showed that the share of newer osteoporotic use of medicines increased continuously, accounting for 34.3% of prescriptions and 26.8% of expenditures in 2019. The study found that in osteoporosis hospital visits under 50 years of age, the use of medicine increased year by year.
However, bone resorption inhibitors and bone formation promoters in this group did not change significantly, accounting for only small proportion.
Source: ResultsAbstract: Conclusion
The development of osteoporosis prescription in this study reflected the current situation of research in China. Meanwhile, in this study, we also investigated the epidemiology of osteoporosis in China in patients under 50 years of age, for whom the incidence of osteoporosis showed an increasing trend, which reminded us to accelerate the prevention of osteoporosis.
Source: ConclusionAuthors’ abstract
Purpose
This study aimed to assess the national trends in osteoporosis prescriptions among Chinese adult outpatients aged less than 50 years with osteoporosis, from 2016 to 2019.
Patients and methods
Prescriptions for adult outpatients with osteoporosis from hospitals in nine major areas were extracted from the database of the Hospitals Prescription Analysis Cooperative Project. Trends in the annual prescriptions and expenditure of osteoporosis were analyzed.
Results
The number of osteoporosis hospital visits showed an increasing trend year by year from 18,412 in 2016 to 23,447 in 2019 (P = 0.029), and the corresponding cost increased from 2,083,872.94 Chinese yuan (CNY) to 2,643,508.59 CNY in 2019 (P = 0.032). The result showed that the share of newer osteoporotic use of medicines increased continuously, accounting for 34.3% of prescriptions and 26.8% of expenditures in 2019. The study found that in osteoporosis hospital visits under 50 years of age, the use of medicine increased year by year.
However, bone resorption inhibitors and bone formation promoters in this group did not change significantly, accounting for only small proportion.
Conclusion
The development of osteoporosis prescription in this study reflected the current situation of research in China. Meanwhile, in this study, we also investigated the epidemiology of osteoporosis in China in patients under 50 years of age, for whom the incidence of osteoporosis showed an increasing trend, which reminded us to accelerate the prevention of osteoporosis.
Publication and source details
Original title: A retrospective analysis of anti-osteoporosis medication trends among patients under 50 years old in nine major regions of China from 2016 to 2019
Bo Chen; Liying Chen; Zhenwei Yu; Yanting Sun; Yuzhen Wang; Chen Wang; Siqi Wang; Yan Hu; Lian-Di Kan; Liu-Cheng Li
PeerJ · 2025
© 2025 Chen et al.2025Chen et al.https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.Zhejiang Provincial Natural Science Foundation of ChinaLQ22H310007 & LYY19H280006Zhejiang Provincial Science Technology Projects of Traditional Chinese Medicine2021ZB174This work was supported by Zhejiang Provincial Natural Science Foundation of China (LQ22H310007), the Zhejiang Provincial Natural Science Foundation of China (No. LYY19H280006), and the Zhejiang Provincial Science Technology Projects of Traditional Chinese Medicine (No. 2021ZB174). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T06:03:53.976318+00:00
DOI: 10.7717/peerj.19187 · PMC11956766